Amgen lands first FDA approval for drug targeting elusive mutation in lung cancer May 28, 2021 Auto Bot Amgen, BioPharma, biopharma nl, California, Clinical Trials, FDA, Non-Small Cell Lung Cancer, Pharma, Sotorasib, Thousand Oaks 0 FDA approval of Amgen drug sotorasib (Lumakras) makes the small molecule the first compound authorized by the regulator for treating cancers characterized by a KRAS G12C mutation. Mutated KRAS proteins had long been regarded “undruggable” targets.